www.finanznachrichten.de ·
68396664 revvity q1 earnings rises guides fy26 plans china unit divestiture 020
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedRevvity's Q1 earnings beat and FY26 guidance indicate stable diagnostics demand. The planned divestiture of its China Immunodiagnostics unit (6% of revenue) reduces China regulatory and geopolitical risk but also removes a growth segment. Impact is company-specific: margin expansion from higher-margin product mix post-divestiture vs. revenue loss. Channel: regulatory (China exposure reduction) and revenue mix shift. No direct commodity or broad sector impact; weak mechanism for broader healthcare sector.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Revvity Q1 net income increased, operating income $75.89M vs $72.23M YoY
- Revenue $711.12M vs $664.76M YoY
- FY26 pro forma revenue guidance $2.81-$2.84B, adj EPS $5.20-$5.30
- Plans to divest China Immunodiagnostics business (~6% of FY25 revenue)
- China unit divestiture expected to be signed Q2 2026, completed 2027